Acceder

Cotización de Mineralys Therapeutics, Inc. (MLYS) hoy en tiempo real

Mineralys Therapeutics, Inc. (MLYS)

Análisis técnico y gráfico histórico de Mineralys Therapeutics, Inc.

Análisis fundamental y estadísticas clave de Mineralys Therapeutics, Inc.

Ficha de Mineralys Therapeutics, Inc. (MLYS)

Ticker MLYS
ISIN US6031701013
Sector Atención sanitaria
Mercado NASDAQ

Análisis financiero de Mineralys Therapeutics, Inc.

Briefing Valoración Rentabilidad Métricas por acción Deuda Liquidez

Resumen financiero e información corporativa de Mineralys Therapeutics, Inc.

Invertir en Mineralys Therapeutics, Inc. en 2026: Preguntas frecuentes

¿Qué es Mineralys Therapeutics, Inc.?

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

¿En qué sector opera Mineralys Therapeutics, Inc.?

Mineralys Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.